CLDX today
$30.15-$0.50 (-1.63%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bearish
1 hourDescending Triangle
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $32.88
Key levels
Resistance$32.88
Resistance$30.92
Support$27.82
Support$25.24
Latest news & SEC filings
AnalystMorgan Stanley keeps Celldex Therapeutics at Overweight, lifts target to $61
AnalystCanaccord Genuity keeps Buy rating on Celldex Therapeutics, lifts target to $68
AnalystMorgan Stanley keeps Overweight on Celldex Therapeutics, lifts target to $61
All CLDX news →About Celldex Therapeutics
Celldex Therapeutics develops antibody-based medicines aimed at immune system pathways and mast cells. Its main candidate, barzolvolimab, targets the KIT receptor and is in testing for skin conditions such as chronic hives, cold-induced hives, dermographism, prurigo nodularis, and eczema. The company is also advancing bispecific antibodies, including CDX-622, for inflammatory disorders. It serves patients with allergic, inflammatory, and autoimmune conditions.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Healthcare
Celldex Therapeutics, Inc. (CLDX)
What Is the Price Target for CLDX?
SEPT Low Target
$45.00
SEPT Mid Target
$66.00
SEPT High Target
$100.00
Analyst Consensus
$66.00
Is CLDX a Buy or Sell Right Now?
Thesis
- •Revenue growing -78.0% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CLDX.
Start Free Trial →Is CLDX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$54.58
25
Moat Score
NONE
1/9
Piotroski Score
15.2
Altman Z-Score
What Is Smart Money Doing with CLDX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CLDX Growth Story
Revenue YoY
-78.0%
3yr Revenue CAGR
-13.1%
EPS Growth YoY
-59.18%
FCF Growth YoY
-33.8%
Revenue Trend
STRONG
Dark Pool Trades for CLDX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CLDX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:38 | $30.15 | 1,929 | $$58K | SELL |
| 21:00:38 | $30.15 | 1,185 | $$36K | SELL |
| 21:00:36 | $30.15 | 3,920 | $$118K | SELL |
| 21:00:36 | $30.15 | 4,100 | $$124K | SELL |
| 21:00:00 | $30.15 | 1,176 | $$35K | SELL |
5 dark pool trades shown · $$371K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Celldex Therapeutics, Inc. (CLDX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CLDX — frequently asked questions
What is CLDX stock price today?
Celldex Therapeutics, Inc. (CLDX) is at $30.15, down 1.63% (-$0.50) at the Nov 11, 2026 close.
Why is CLDX stock moving today?
Latest CLDX news — Nov 9, 2026: Morgan Stanley keeps Celldex Therapeutics at Overweight, lifts target to $61 · Nov 9, 2026: Canaccord Genuity keeps Buy rating on Celldex Therapeutics, lifts target to $68
Why did CLDX stock move on Nov 9, 2026?
Celldex Therapeutics shares rose 3.44% to close at $31.24 on above-average volume of 1,572,488 shares. The move followed bullish analyst actions, with Morgan Stanley reiterating an Overweight rating and raising its price target to $61, while Canaccord Genuity maintained a Buy rating and lifted its target to $68.
What is the CLDX price target?
The average analyst price target for CLDX is $66.00, ranging from $45 to $100, based on 10 analysts. Latest: Canaccord Genuity maintains on Nov 9, 2026.
What do analysts rate CLDX?
Analyst ratings for CLDX: 14 Buy, 1 Hold, 0 Sell — consensus Strong Buy.
Did CLDX beat earnings?
CLDX last reported on Nov 5, 2026: EPS -$0.96 vs -$1.02 expected — a beat of 5.9%.
Does CLDX pay a dividend?
CLDX does not currently pay a dividend.
What are CLDX support and resistance levels?
Support: $27.82, $25.24, $22.45. Resistance: $30.92, $32.88, $34.94.
What are insiders doing with CLDX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on CLDX?
Nov 9, 2026: Morgan Stanley keeps Celldex Therapeutics at Overweight, lifts target to $61 · Nov 9, 2026: Canaccord Genuity keeps Buy rating on Celldex Therapeutics, lifts target to $68 · Nov 9, 2026: Morgan Stanley keeps Overweight on Celldex Therapeutics, lifts target to $61